Adenoviral vector programs are too complex for a rigid, one-size-fits-all manufacturing approach. Construct design, cell line behavior, harvest conditions, purification strategy, formulation, analytics, and viral clearance can all shape the path from development to GMP.
In this Fierce Biotech article, SK pharmteco experts explain why adenoviral manufacturing requires an adaptive, adenovirus-specific platform—one that standardizes where possible while tailoring critical process decisions to the biology of each program.
Learn how SKyvecTM Adeno is designed to help developers identify process vulnerabilities earlier, strengthen analytical readiness, and move with greater confidence toward GMP manufacturing.
Read the full article to explore how an adaptive adenoviral platform can de-risk development from process design to clinical advancement.
Authors: Tatiana Nanda, VP, Technical Development and Analytical Services, SK pharmteco; Christopher Nieder, Senior Director, Head of Technical Development, SK pharmteco; Mardhani Aparajithan, Director, MSAT, SK pharmteco; and Robert Brousseau, Senior Content Manager, SK pharmteco